news
REGEN-COV prevents symptomatic COVID-19 infections, finds analysis
Interim data from the Phase III trial evaluating REGEN-COV™ as a passive vaccine to prevent COVID-19 finds it reduces overall infection rate, viral load and length of infection.
List view / Grid view
US Food and Drug Administration (FDA)
news
Voclosporin approved by FDA to treat lupus nephritis
The FDA has approved Aurinia Pharmaceuticals' LupkynisTM(voclosporin) for the treatment of lupus nephritis, alongside standard-of-care.
news
FDA approves first extended-release injectable, complete regimen for HIV
The approval of Cabenuva (cabotegravir and rilpivirine, injectable formulation) means HIV infected adults could receive once-monthly injections to manage their condition.
news
FDA approves crizotinib for children with certain anaplastic large cell lymphomas
In a Phase I/II trial, 81 percent of paediatric patients with relapsed or refractory, systemic anaplastic large cell lymphoma achieved complete remission with crizotinib (Xalkori).
news
US could purchase over 1.5 million doses of Regeneron’s COVID-19 antibody cocktail
The additional doses of casirivimab and imdevimab, two monoclonal antibodies, will be used in non-hospitalised COVID-19 patients.
news
Baricitinib and remdesivir reduce time to recovery in COVID-19 patients
A clinical trial in hospitalised COVID-19 patients has demonstrated that baricitinib and remdesivir reduce time to recovery.
news
FDA approves Phase III trial of synthetic biological COVID-19 treatment
The international Phase III trial will evaluate whether a 14 day course of carrimycin can improve outcomes for COVID-19 patients with severe symptoms.
news
FDA monitoring impact of SARS-CoV-2 mutations
The FDA has alerted clinical laboratory staff and healthcare providers that it is monitoring the potential impact of SARS-CoV-2 mutations, including the UK variant.
news
New process for producing synthetic insulin developed
Researchers say that their novel way to produce synthetic insulin could also be used to create at least eight other drugs.
news
Trial to evaluate monoclonal antibody therapy for mild-to-moderate COVID-19
The study will determine if the combination of BRII-196 and BRII-198, two investigational antibodies for SARS-CoV-2, can prevent disease progression.
news
FDA approves Ebanga (Ansuvimab-zykl) for the treatment of Ebola
Ebanga was approved based on its ability to reduce 28-day mortality in patients with confirmed Ebolavirus infection.
article
The rise of biosimilars – navigating regulatory complexity in Europe
Gabriela Marton sets out some of the EU-associated regulatory challenges life sciences companies will need to navigate if they want to take advantage of the rise of biosimilars.
article
Why cold chain requirements are not holding COVID-19 vaccines back
Despite the stringent storage conditions required for Pfizer and BioNTech’s COVID-19 vaccine, the need for a return to normal life has levelled the playing field for all candidate prophylactics against SARS-CoV-2.
article
Pioneering a full-ecosystem microbiota approach to improve survival outcomes in life-threatening diseases
The human gut contains the largest ecosystem of microbial species having complex host-microbiome interactive networks that contribute to our physiology and regulate our immune system. An imbalance in this host-microbiome interaction is associated with disease and the ability to restore or stabilise the network by introducing a rich and diverse…
article
Current innovations in the vaccine pipeline
As the global COVID-19 response continues, so does the rapidly expanding pipeline for a novel COVID-19 vaccine. Here, experts from Avalere Health outline ongoing US and global vaccine development efforts, including the role of public-private partnerships in accelerating vaccine development. They will also focus on the broader context of respiratory…
